Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ryvu TherapeuticsWAR:RVU -1.80%66 Gross Margin % is 75.63% as of Mar. 2026, which is 28% above its 10-year median of 58.93. GuruFocus rates WAR:RVU with a GF Score™ of 66/100 and a GF Value™ of zł45.84 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 732 Biotechnology companies, Ryvu Therapeutics ranks better than 66.94% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Ryvu Therapeutics had a gross margin of 75.63% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Ryvu Therapeutics Gross Margin % Related Terms
Ryvu Therapeutics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Ryvu Therapeutics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:RVU vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Ryvu Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ryvu Therapeutics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Ryvu Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Ryvu Therapeutics (WAR:RVU) has a Gross Margin % of 75.63% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Ryvu Therapeutics and its competitors. This is 28% above median its historical median of 58.93. According to the industry distribution chart, Ryvu Therapeutics ranks #242 out of 732 companies in the Biotechnology industry, placing it in the top 33.1%.
Is Ryvu Therapeutics' Gross Margin % too high?
Ryvu Therapeutics' current Gross Margin % of 75.63% is 28% above median its 10-year median of 58.93. The Biotechnology industry median Gross Margin % is 60.91. Ryvu Therapeutics' value of 75.63% is 24.2% above this industry median. Based on the distribution chart, Ryvu Therapeutics ranks #242 out of 732 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ryvu Therapeutics has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ryvu Therapeutics' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ryvu Therapeutics ranks #242 out of 732 companies for Gross Margin %. This puts Ryvu Therapeutics in the upper half of its industry. The industry median Gross Margin % is 60.91. Ryvu Therapeutics' value of 75.63% is 24.2% above this benchmark. While the company's 10-year median is 58.93 vs. the industry median of 60.91, Ryvu Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ryvu Therapeutics's current Gross Margin % of 75.63% is 24.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Ryvu Therapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ryvu Therapeutics's current Gross Margin % is 75.63%, which is 28% above median its own 10-year median of 58.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryvu Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ryvu Therapeutics (WAR:RVU) is currently considered Possible Value Trap. The stock's GF Value™ is zł45.84, compared to a current price of zł15.30 — trading 66.6% below its estimated fair value. The current Gross Margin % is 75.63%, which is 28% above median its 10-year median of 58.93 and 24.2% above the Biotechnology industry median of 60.91. Ryvu Therapeutics' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Ryvu Therapeutics (WAR:RVU), the current Gross Margin % is 75.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ryvu Therapeutics (WAR:RVU) Overvalued in 2026?
Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued.
The current stock price of zł15.30 is trading 66.6% below its estimated GF Value™ of zł45.84.
GuruFocus considers Ryvu Therapeutics to be Possible Value Trap.
Key valuation signals for WAR:RVU:
Gross Margin %: 75.63% (28% above median its 10-year median of 58.93)
GF Value™: zł45.84 vs. price of zł15.30 (66.6% below fair value)
Industry Position: 24.2% above the Biotechnology median (#242 of 732)
No single metric tells the full story. See the WAR:RVU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
66GF Score
Get the complete analysis for WAR:RVU
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:RVU has been successfully added to your 
